Health Care & Life Sciences » Biotechnology | Sorrento Therapeutics Inc.

Sorrento Therapeutics Inc. | Ownership

Companies that own Sorrento Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
SSgA Funds Management, Inc.
7,232,063
6.2%
2,073,717
0%
06/30/2018
BlackRock Fund Advisors
5,379,888
4.61%
3,982,589
0%
06/30/2018
The Vanguard Group, Inc.
4,327,828
3.71%
1,312,930
0%
06/30/2018
D. E. Shaw & Co. LP
1,012,823
0.87%
309,451
0.01%
06/30/2018
Northern Trust Investments, Inc.
959,067
0.82%
802,965
0%
06/30/2018
Geode Capital Management LLC
772,318
0.66%
280,542
0%
06/30/2018
Franklin Templeton SinoAm Securities Investment Mgmt, Inc
651,690
0.56%
651,690
0.42%
03/31/2018
Intellectus Partners LLC
557,026
0.48%
-797,422
0.56%
06/30/2018
The Rock Creek Group LP
460,000
0.39%
0
0.69%
06/30/2018
Wildcat Capital Management LLC
415,765
0.36%
0
1.7%
06/30/2018

About Sorrento Therapeutics

View Profile
Address
4955 Directors Place
San Diego California 92121
United States
Employees -
Website http://www.sorrentotherapeutics.com
Updated 07/08/2019
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.